COVID-19 Pandemic and Female Sexual Behavior
Effect of SARS- COVID-19 Pandemic on Female Sexual Behavior
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Coronaviruses are a group of RNA viruses that affect mainly the respiratory system and cause the common cold, fever, and coughs in mammals and birds. However, in some cases, coronaviruses are associated with more serious and lethal conditions, such as pneumonia, bronchitis, and severe acute respiratory syndrome. A novel coronavirus (SARS-CoV-2) originating from Wuhan, China led to a global health crisis. At the time of writing, SARS-CoV-2 infected more than two million, resulting in almost 180.000 deaths. World Health Organization declared new SARS-CoV-2 infection a pandemic, and many states enacted strict, rules such as border closures, transportation restrictions, and quarantine.
The term 'sexual behavior' encompasses a large spectrum of actions in which humans present their sexuality. Previous reports have analyzed the effect of mass disasters on female sexual behavior.
Many studies in the literature have described the relationship between mass disasters and female sexual behavior, but none have investigated the effect of the SARS-CoV-2 pandemic on women's sexual attitude. The aim of this study is therefore to evaluate the effect of the SARS-CoV-2 pandemic on female sexual behavior.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey, 34104
- Haseki Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
From February 2018 to September 2019. For each participant, detailed medical history was obtained, including age, body mass index (BMI), education and income level, presence of comorbidities and the number of previous deliveries. Other details noted were menstrual status of patients, frequency of sexual intercourse and desire for fertility. All patients were asked to fill out the Female Sexual Function Index (FSFI) form. Patients' data were recorded in the electronic data system, prospectively.
To identify the effect of SARS-CoV-2 pandemic on female sexual behavior, the investigators conducted an observational study to compare the frequency of sexual intercourse, desire for fertility, FSFI score, contraception type and presence of vaginal infection between pandemic era (March 11th and April 12th 2020) and 6-12 months prior to the pandemic.
Description
Inclusion Criteria:
- married
- above 18 yo
- premenopausal status
Exclusion Criteria:
- urinary incontinence
- history of gynecologic operation
- malignancy
- psychiatric or neurologic disease diagnosis
- being infected by HBV HCV or HIV
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
1
study group pre-pandemic time interval
|
sexual behavior Questionaire
|
|
2
same population during pandemic
|
sexual behavior Questionaire
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FSFI (Female Sexual Function Index)SCORE difference
Time Frame: 1 year
|
the FSFI SCORE difference between pre and during pandemic
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Med. 2020 Feb;46(2):357-360. doi: 10.1007/s00134-020-05954-2. Epub 2020 Feb 5. No abstract available.
- Liu S, Han J, Xiao D, Ma C, Chen B. A report on the reproductive health of women after the massive 2008 Wenchuan earthquake. Int J Gynaecol Obstet. 2010 Feb;108(2):161-4. doi: 10.1016/j.ijgo.2009.08.030. Epub 2009 Nov 4.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AcibademU cov
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.